|
|
Vaccine Detail
|
A2/4-1BBL melanoma vaccine |
| Vaccine Information |
- Vaccine Name: A2/4-1BBL melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Live, attenuated vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: 4-1BBL (NCT01898039)
- Immunization Route: Intravenous injection (i.v.)
- Description: The A2/4-1BBL melanoma vaccine is used to treat patients with malignant melanoma. It is made of a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation, with an immune response to residual tumor in the body. It will be used in combination with intravenous low dose cyclophosphamide, 300 mg/m2. (NCT01898039)
|
| Host Response |
|
|
| References |
NCT01898039: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [https://clinicaltrials.gov/study/NCT01898039]
|
|
